Kadmon Holdings, Inc.
DelistedCIK 1557142fmd_1ZQ4EQ7H0AWXKMHCP1YQ80F4M2Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2014 to Sep 30, 2021, 28 periods
| Line item | FY2014 | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 |
|---|---|---|---|---|---|---|---|
| Total revenues | 95 | 36 | 26 | 12 | 1 | 5 | 8 |
| Cost of revenue | – | – | 4 | 3 | 1 | – | – |
| Gross profit | 84 | 30 | 22 | 9 | 1 | 4 | 6 |
| Realized investment gains (losses) | – | – | – | – | 34 | – | – |
| Research and development | 33 | 34 | 36 | 41 | 49 | 56 | 65 |
| Selling, general and administrative | 89 | 105 | 106 | 37 | 38 | 36 | 43 |
| Total operating expenses | 122 | 170 | 138 | 78 | 87 | 93 | 109 |
| Operating income | (38) | (140) | (115) | (69) | (86) | (89) | (102) |
| Interest expense | 29 | 27 | 73 | 6 | 5 | 3 | 0 |
| Interest and investment income | 0 | 0 | 0 | 0 | 1 | 2 | 1 |
| Other non-operating income (expense) | (26) | (7) | (93) | (11) | 31 | 28 | (7) |
| Income before taxes | (64) | (147) | (208) | (80) | (55) | (61) | (109) |
| Income tax expense | (0) | (0) | 0 | (0) | (1) | 0 | (0) |
| Net income from continuing operations | (64) | (147) | (209) | (80) | (54) | (61) | (109) |
| Net income | (64) | (147) | (209) | (80) | (54) | (61) | (109) |
| Net income to common shareholders | (64) | (147) | (230) | (82) | (56) | (63) | (111) |